Drugs / Tedopi
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04884282 | Oct 2021 → Sep 2027 expected | non-small cell lung carcinoma | Fondazione Ricerca Traslazionale | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tedopi | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04884282 ↗ |
| Modality | Vaccine | “Tedopi®, a cancer vaccine” PMID 36946237 ↗ Mar 2023 |